Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

l session, results of an ongoing trial of ISIS 301012 added to maximal lipid lowering therapies in homozygous familial hypercholesterolemia (FH) patients were reported. Results of polygenic hypercholesterolemic patients treated with up to 400 mg/week of ISIS 301012 for up to three months as a single agent are the subject of a v-cast poster presentation. Results for the extended three-month treatment cohorts at 200 and 300 mg/week doses in the statin coadministration study are expected later in the year. Also later in the year, results from an ongoing double-blind, placebo-controlled, dose-escalation study in patients with heterozygous FH will be reported.

ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH and Isis plans to begin registration-directed studies for FH in 2007.

About ISIS 301012 and Cholesterol

ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop ISIS 301012 as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins.

Adult Treatment Panel III Recommendations

The National Cholesterol Education Program's Adult Treatment Panel III guidelines for target LDL-C levels High-Risk patients is less than 100 mg/dL, with an optional target
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:10/1/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... technology used to develop and produce enzymes and ... and industrial enzymes industries, today announced the receipt ... for commercial scale production of Abengoa,s proprietary cellulase ... under Abengoa,s license agreement with Dyadic. ...
(Date:10/1/2014)...  ResMed (NYSE: RMD ), a pioneer and ... design complete sleep apnea solutions specifically for women, is launching ... a good night,s sleep. The Better Sleep ... tired is just part of living a busy life. It ... pillar of health, essential to not only living an active ...
(Date:10/1/2014)... MIAMI , Oct. 1, 2014 NeuroCall, ... Commission accreditation for its Telestroke and Teleneurology services. Dr. ... of NeuroCall, commented, "We are extremely proud that our ... Commission, as we continue to provide lifesaving support and ... of affiliated hospitals throughout the United States ...
Breaking Medicine Technology:Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3NeuroCall Awarded Joint Commission Accreditation 2
... 8, 2011 PermaDerm™, an engineered skin substitute which ... prepared from a patient,s own skin cells, has been ... that the U.S. Department of Defense awarded more than ... of the therapeutic candidate for the treatment of severe ...
... a Carmel-headquartered software development and solutions firm has been ... 500 and mid-market businesses throughout the world since 1983. ... its extensive supply chain experience to develop supply chain ... Blue Horseshoe Intellectual Property (BHIP). Led ...
Cached Medicine Technology:PermaDermâ„¢ Receives National Media Coverage 2Software Development Firm's New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain 2Software Development Firm's New Intellectual Property Group, Blue Horseshoe IP Creates Solutions to Help Customers Optimize Supply Chain 3
(Date:10/1/2014)... The peptide a small protein beta-amyloid is strongly associated ... unequivocal proof that this peptide is the causal agent ... main obstacle impeding such confirmation is that beta-amyloid is ... it aggregates, that is when it self-assembles to form ... with a single target, beta-amyloid alone, but with multiple ...
(Date:10/1/2014)... Physical Sciences Research Council (EPSRC) will focus on ... systems which run, for example, manufacturing plants, power ... , The research will help understand and ... systems behind our critical national infrastructure. , ... (RITICS), based at Imperial College London, is co-ordinating ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog post explaining how ... Senior citizens can qualify for affordable term life insurance ... are over 50 years old. Some term life insurance ... , Term life insurance with a simplified issue can ... life insurance during retirement is important for covering funeral ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Farmington ... including a redefined mission and visual identity helping ... of partnering with them to create greater benefit ... brand that focuses on empowering customers to better ... , The crown jewel of the rebrand is ...
Breaking Medicine News(10 mins):Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Farmington Company Launches Rebrand and New Positioning 2
... therapy still recommended over steroid injections, researchers say , ... the eye slowed diabetes-related eye disease, though lasers remain ... to the steroids, new research shows. , Researchers from ... and women who had diabetic retinopathy with macular edema ...
... , , WESTON, Fla., Dec. 31 ... annual meeting of shareholders on December 28, 2009 was adjourned due ... not sufficient shares present in person or by proxy to constitute ... adjourned the Annual Meeting in order to permit further solicitations of ...
... and comfort to hospice patients and their families , THURSDAY, ... help Alzheimer,s patients remember and autistic children calm down. Now, ... guitar to comfort dying patients in hospice. , Families gathered ... hymns, such as "Amazing Grace," while others ask for favorite ...
... ... it was put to the ultimate test in a double-blind, randomized study. , ... Manhasset, NY (Vocus) December 31, 2009 -- ... it was put to the ultimate test in a double-blind, randomized study. It turned out ...
... , ... a joint press release of Hiru Corporation (HIRU) and Hard to ... the finalization and completion of the purchase and sale of the ... stock basis can be found at the Pink Sheets web site ...
... Conn., Dec. 31 Metabolife, a leading brand in the weight ... Spectacular introduces, "My Resolution" a part of Metabolife,s online community dedicated ... healthier person for the New Year. , "We know ... so we created a place for individuals to share their resolutions ...
Cached Medicine News:Health News:Laser Deemed Best Treatment for Diabetic Retinopathy 2Health News:American Scientific Resources 2009 Annual Meeting of Shareholders Adjourned 2Health News:Her Music Eases the End for Dying Patients 2Health News:Her Music Eases the End for Dying Patients 3Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 2Health News:Despite Earlier Doubts, Feinstein Study Shows Fetal Transplants May Benefit Parkinson's Patients Over Age 60 3Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 2Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 3Health News:Hard To Treat Diseases (HTDS) Finalizes Sale Of Its MindUp BioResearch Division To (HIRU) 4Health News:Metabolife(R) Helps People Nationwide Start off the New Year Right as the Presenting Sponsor of the 2009 Brian Boitano Skating Spectacular 2Health News:Metabolife(R) Helps People Nationwide Start off the New Year Right as the Presenting Sponsor of the 2009 Brian Boitano Skating Spectacular 3
... / gel tubes are for the ... diagnostics and for viral load determinations. ... remain stable at room temperature for ... results, it is recommended to centrifuge ...
BD Vacutainer® spray-coated K2EDTA tubes are used for whole blood hematology determinations and immunohematology testing....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
We offer small and large pre-gelled Surface Electrodes suitable for EMG or EGG recordings....
Medicine Products: